X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
PULM-001 data shown to prevent and treat acute respiratory distress syndrome due to SARS-CoV-2 infection and reduce mortality from 40% to 0% in a small, randomized clinical trial.
Lead Product(s): Dapsone
Therapeutic Area: Infections and Infectious Diseases Product Name: PULM-001
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 22, 2021
Details:
The Phase III Clinical Trial is sponsored by the Research Institute of the McGill University Health Centre (RI-MUHC) and will be conducted in seven centres in Canada and the United States as soon as the necessary funding has been secured.
Lead Product(s): Dapsone
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: McGill University Health Centre
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 02, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
